A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

July 5, 2018

Study Completion Date

July 5, 2018

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

Faster aspart

An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.

DRUG

Insulin aspart (NovoRapid®)

An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.

Trial Locations (1)

Novo Nordisk Investigational Site, Hanover